Logo image of ALVO

ALVOTECH SA (ALVO) Stock Fundamental Analysis

NASDAQ:ALVO - Nasdaq - LU2458332611 - Common Stock - Currency: USD

8.22  +0.28 (+3.53%)

After market: 8.22 0 (0%)

Fundamental Rating

4

Taking everything into account, ALVO scores 4 out of 10 in our fundamental rating. ALVO was compared to 567 industry peers in the Biotechnology industry. ALVO has a bad profitability rating. Also its financial health evaluation is rather negative. ALVO is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ALVO has reported negative net income.
In the past year ALVO has reported a negative cash flow from operations.
In the past 5 years ALVO always reported negative net income.
In the past 5 years ALVO always reported negative operating cash flow.
ALVO Yearly Net Income VS EBIT VS OCF VS FCFALVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

With a decent Return On Assets value of -18.98%, ALVO is doing good in the industry, outperforming 79.54% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 5.35%, ALVO belongs to the top of the industry, outperforming 94.00% of the companies in the same industry.
Industry RankSector Rank
ROA -18.98%
ROE N/A
ROIC 5.35%
ROA(3y)-46.35%
ROA(5y)-38.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALVO Yearly ROA, ROE, ROICALVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

Looking at the Operating Margin, with a value of 14.16%, ALVO belongs to the top of the industry, outperforming 95.24% of the companies in the same industry.
ALVO has a better Gross Margin (62.33%) than 78.31% of its industry peers.
Industry RankSector Rank
OM 14.16%
PM (TTM) N/A
GM 62.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALVO Yearly Profit, Operating, Gross MarginsALVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

2

2. Health

2.1 Basic Checks

ALVO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ALVO has been increased compared to 1 year ago.
The debt/assets ratio for ALVO has been reduced compared to a year ago.
ALVO Yearly Shares OutstandingALVO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100M 200M 300M
ALVO Yearly Total Debt VS Total AssetsALVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -1.02, we must say that ALVO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.02, ALVO is in the better half of the industry, outperforming 60.32% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.02
ROIC/WACC0.73
WACC7.34%
ALVO Yearly LT Debt VS Equity VS FCFALVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

A Current Ratio of 2.35 indicates that ALVO has no problem at all paying its short term obligations.
ALVO has a worse Current ratio (2.35) than 71.78% of its industry peers.
ALVO has a Quick Ratio of 1.69. This is a normal value and indicates that ALVO is financially healthy and should not expect problems in meeting its short term obligations.
ALVO has a Quick ratio of 1.69. This is in the lower half of the industry: ALVO underperforms 78.84% of its industry peers.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 1.69
ALVO Yearly Current Assets VS Current LiabilitesALVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 64.39% over the past year.
Looking at the last year, ALVO shows a very strong growth in Revenue. The Revenue has grown by 426.84%.
ALVO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 42.86% yearly.
EPS 1Y (TTM)64.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)426.84%
Revenue growth 3Y131.44%
Revenue growth 5Y42.86%
Sales Q2Q%0%

3.2 Future

ALVO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.08% yearly.
The Revenue is expected to grow by 43.33% on average over the next years. This is a very strong growth
EPS Next Y104.4%
EPS Next 2Y59.35%
EPS Next 3Y44.08%
EPS Next 5YN/A
Revenue Next Year42.14%
Revenue Next 2Y43.93%
Revenue Next 3Y43.33%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ALVO Yearly Revenue VS EstimatesALVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 500M 1B 1.5B
ALVO Yearly EPS VS EstimatesALVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALVO. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 17.52, ALVO is valued on the expensive side.
Based on the Price/Forward Earnings ratio, ALVO is valued cheaper than 94.36% of the companies in the same industry.
ALVO's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 20.86.
Industry RankSector Rank
PE N/A
Fwd PE 17.52
ALVO Price Earnings VS Forward Price EarningsALVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

ALVO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALVO is cheaper than 94.18% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 35.86
ALVO Per share dataALVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ALVO's earnings are expected to grow with 44.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y59.35%
EPS Next 3Y44.08%

More info and screens

0

5. Dividend

5.1 Amount

ALVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALVOTECH SA

NASDAQ:ALVO (5/2/2025, 8:00:00 PM)

After market: 8.22 0 (0%)

8.22

+0.28 (+3.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26 2025-03-26/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners5.83%
Inst Owner ChangeN/A
Ins Owners0.61%
Ins Owner ChangeN/A
Market Cap2.48B
Analysts78
Price Target18.36 (123.36%)
Short Float %0.74%
Short Ratio6.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.98%
Min EPS beat(2)38.96%
Max EPS beat(2)64.99%
EPS beat(4)3
Avg EPS beat(4)2040.9%
Min EPS beat(4)-990.69%
Max EPS beat(4)9050.33%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)21.9%
Min Revenue beat(2)13.45%
Max Revenue beat(2)30.36%
Revenue beat(4)2
Avg Revenue beat(4)5.53%
Min Revenue beat(4)-19.62%
Max Revenue beat(4)30.36%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.7%
PT rev (3m)-11.11%
EPS NQ rev (1m)-558.33%
EPS NQ rev (3m)-711.11%
EPS NY rev (1m)-83.67%
EPS NY rev (3m)-76.92%
Revenue NQ rev (1m)-8.35%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)13.56%
Revenue NY rev (3m)-2.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 17.52
P/S 5.04
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 35.86
EPS(TTM)-0.87
EYN/A
EPS(NY)0.47
Fwd EY5.71%
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS1.63
BVpS-1.37
TBVpS-1.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.98%
ROE N/A
ROCE 6.77%
ROIC 5.35%
ROICexc 5.63%
ROICexgc 5.82%
OM 14.16%
PM (TTM) N/A
GM 62.33%
FCFM N/A
ROA(3y)-46.35%
ROA(5y)-38.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 11.37
Cap/Depr 182.1%
Cap/Sales 11.59%
Interest Coverage 1.27
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.35
Quick Ratio 1.69
Altman-Z -1.02
F-Score5
WACC7.34%
ROIC/WACC0.73
Cap/Depr(3y)204.72%
Cap/Depr(5y)182.09%
Cap/Sales(3y)39.66%
Cap/Sales(5y)47.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y104.4%
EPS Next 2Y59.35%
EPS Next 3Y44.08%
EPS Next 5YN/A
Revenue 1Y (TTM)426.84%
Revenue growth 3Y131.44%
Revenue growth 5Y42.86%
Sales Q2Q%0%
Revenue Next Year42.14%
Revenue Next 2Y43.93%
Revenue Next 3Y43.33%
Revenue Next 5YN/A
EBIT growth 1Y119.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year175.44%
EBIT Next 3Y88.38%
EBIT Next 5YN/A
FCF growth 1Y18.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.13%
OCF growth 3YN/A
OCF growth 5YN/A